Immune oncology (IO) and metastatic lung cancer [CBD]: Curability, bony metastasis and duration of therapy

The introduction of immune checkpoint inhibitors (ICI) instigated significant improvement in the management of metastatic NSCLC. Currently, metastatic NSCLC remains in the category of ‘incurable’ malignancies and there is no biologic or mechanistic basis to guide the duration of treatment with immun...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hunter C Cochran, Yadav Pandey, Richard W. Nicholas, Eric J. Del Giacco, A. Mazin Safar
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Cure Immune oncology immune checkpoint inhibitors bone metastasis Duration of immunetherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/ca44d3c5070c4ceea8cf2379ae04ca66
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ca44d3c5070c4ceea8cf2379ae04ca66
record_format	dspace
spelling	oai:doaj.org-article:ca44d3c5070c4ceea8cf2379ae04ca662021-11-20T05:14:46ZImmune oncology (IO) and metastatic lung cancer [CBD]: Curability, bony metastasis and duration of therapy2666-621910.1016/j.cpccr.2021.100129https://doaj.org/article/ca44d3c5070c4ceea8cf2379ae04ca662021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2666621921000776https://doaj.org/toc/2666-6219The introduction of immune checkpoint inhibitors (ICI) instigated significant improvement in the management of metastatic NSCLC. Currently, metastatic NSCLC remains in the category of ‘incurable’ malignancies and there is no biologic or mechanistic basis to guide the duration of treatment with immunotherapy. Generally, ICIs are continued until progression, unacceptable toxicity occurs or for an arbitrary 2 years. We present a case of stage IV NSCLC with bulky disease and several adverse prognostic factors who demonstrated remarkable benefits, arguably amounting to cure using a much shorter pembrolizumab course (4 months) and has remained free of progression off cancer therapy for 42 months. This case raises several important points regarding the current treatment approach and objective in metastatic NSCLC. Moreover, we argue that the management of metastatic bone disease may need reconsideration when immunotherapy is used considering the known adverse impact of radiation on immune cells. Lastly, we propose the consideration of c-reactive protein as a putative marker which may function as an objective tracer of metastatic activity providing the oncologist with a useful tool in managing such patients with ICI.Hunter C CochranYadav PandeyRichard W. NicholasEric J. Del GiaccoA. Mazin SafarElsevierarticleCureImmune oncologyimmune checkpoint inhibitorsbone metastasisDuration of immunetherapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCurrent Problems in Cancer: Case Reports, Vol 4, Iss , Pp 100129- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Cure Immune oncology immune checkpoint inhibitors bone metastasis Duration of immunetherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Cure Immune oncology immune checkpoint inhibitors bone metastasis Duration of immunetherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Hunter C Cochran Yadav Pandey Richard W. Nicholas Eric J. Del Giacco A. Mazin Safar Immune oncology (IO) and metastatic lung cancer [CBD]: Curability, bony metastasis and duration of therapy
description	The introduction of immune checkpoint inhibitors (ICI) instigated significant improvement in the management of metastatic NSCLC. Currently, metastatic NSCLC remains in the category of ‘incurable’ malignancies and there is no biologic or mechanistic basis to guide the duration of treatment with immunotherapy. Generally, ICIs are continued until progression, unacceptable toxicity occurs or for an arbitrary 2 years. We present a case of stage IV NSCLC with bulky disease and several adverse prognostic factors who demonstrated remarkable benefits, arguably amounting to cure using a much shorter pembrolizumab course (4 months) and has remained free of progression off cancer therapy for 42 months. This case raises several important points regarding the current treatment approach and objective in metastatic NSCLC. Moreover, we argue that the management of metastatic bone disease may need reconsideration when immunotherapy is used considering the known adverse impact of radiation on immune cells. Lastly, we propose the consideration of c-reactive protein as a putative marker which may function as an objective tracer of metastatic activity providing the oncologist with a useful tool in managing such patients with ICI.
format	article
author	Hunter C Cochran Yadav Pandey Richard W. Nicholas Eric J. Del Giacco A. Mazin Safar
author_facet	Hunter C Cochran Yadav Pandey Richard W. Nicholas Eric J. Del Giacco A. Mazin Safar
author_sort	Hunter C Cochran
title	Immune oncology (IO) and metastatic lung cancer [CBD]: Curability, bony metastasis and duration of therapy
title_short	Immune oncology (IO) and metastatic lung cancer [CBD]: Curability, bony metastasis and duration of therapy
title_full	Immune oncology (IO) and metastatic lung cancer [CBD]: Curability, bony metastasis and duration of therapy
title_fullStr	Immune oncology (IO) and metastatic lung cancer [CBD]: Curability, bony metastasis and duration of therapy
title_full_unstemmed	Immune oncology (IO) and metastatic lung cancer [CBD]: Curability, bony metastasis and duration of therapy
title_sort	immune oncology (io) and metastatic lung cancer [cbd]: curability, bony metastasis and duration of therapy
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/ca44d3c5070c4ceea8cf2379ae04ca66
work_keys_str_mv	AT hunterccochran immuneoncologyioandmetastaticlungcancercbdcurabilitybonymetastasisanddurationoftherapy AT yadavpandey immuneoncologyioandmetastaticlungcancercbdcurabilitybonymetastasisanddurationoftherapy AT richardwnicholas immuneoncologyioandmetastaticlungcancercbdcurabilitybonymetastasisanddurationoftherapy AT ericjdelgiacco immuneoncologyioandmetastaticlungcancercbdcurabilitybonymetastasisanddurationoftherapy AT amazinsafar immuneoncologyioandmetastaticlungcancercbdcurabilitybonymetastasisanddurationoftherapy
_version_	1718419509398732800

Immune oncology (IO) and metastatic lung cancer [CBD]: Curability, bony metastasis and duration of therapy

Ejemplares similares